Advances in Diagnosing and Treating High-Risk Multiple Myeloma
High-risk multiple myeloma (MM) is a challenging condition to diagnose and treat, requiring effective tools to identify patients and deliver targeted therapies....
CNP, DipACLM Nurse Practitioner, Massachusetts General Hospital
Patient Management Guidelines
National Comprehensive Cancer Network Clinical Practice Guidelines
The National Comprehensive Cancer Network Clinical Practice Guidelines has evidence-based guidance on the diagnosis, workup, and management of multiple myeloma.
These guidelines provide recommendations on treatment for both patients who are newly diagnosed with multiple myeloma and patients who have relapsed/refractory disease, plasma cell leukemia, solitary plasmacytoma, and smoldering myeloma.
Evaluating MRD Detection Methods in High-Risk Smoldering Multiple Myeloma: Sensitivity and Prognosis
This study evaluated the performance of mass spectrometry (MS), serum protein electrophoresis /immunofixation electrophoresis (IFE), and next-generation flow cytometry (NGF) for detecting minimal residual disease (MRD) in patients with high-risk...
Multiparametric Flow Cytometry -Based MRD Assessment With DURAClone for Multiple Myeloma Post-ASCT
This study aimed to develop a multiparametric flow cytometry-based minimal residual disease (MRD) assessment protocol using the DURAClone method for patients with multiple myeloma (MM), particularly after autologous stem cell...
CHIP Tied to Higher CVD Risk in Patients With Multiple Myeloma Undergoing HCT
Researchers of a study investigating the role of clonal hematopoiesis of indeterminate potential (CHIP) in cardiovascular disease (CVD) among patients with multiple myeloma (MM) undergoing hematopoietic stem cell transplant (HCT)...
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Revealing Multiple Myeloma Origins: Premalignant Disorders and Biomarker Advances
Preexisting plasma cell disorders, such as monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM), are identified in at least one-third of patients with multiple myeloma (MM)....
Challenges and Hope in Treating RRMM: Insights from the LocoMMotion Study
Researchers from the LocoMMotion study examined real-world clinical practice treatments for patients with relapsed/refractory multiple myeloma (RRMM) exposed to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies....
Multiple Myeloma Advances Call for Standardized IgG-RT to Tackle Immune Challenges
Recent advancements in multiple myeloma (MM) therapies have extended survival but introduced immunosuppressive challenges, including hypogammaglobulinemia, which increases infection risk. T-cell engaging therapies have improved outcomes for heavily pretreated patients,...
